Source Count: 21 | Weighted Score: 45 | Source Confidence: [5/5] | Primary Tier: 1 | Last Updated: March 14, 2026
Keywords: cell-free DNA, cfDNA, liquid biopsy, circulating tumor DNA, ctDNA, non-invasive prenatal testing, NIPT, cancer detection, fragmentation, methylation
Category Tags: molecular-biology, diagnostics, cancer, genomics, prenatal
Cross-References: Z_5_08 — DNA · Z_5_09 — Single-Cell Genomics · X_1_14 — Medical Science

QUICK SUMMARY

Circulating cell-free DNA (cfDNA) — fragments of DNA released into the bloodstream and other body fluids through cell death (apoptosis, necrosis), active secretion, and other mechanisms — has emerged as a revolutionary tool for non-invasive diagnostics across multiple medical domains. First detected by Mandel and Métais in 1948 (decades before its clinical significance was appreciated), cfDNA circulates in the blood as short fragments (~167 bp — corresponding to the DNA wrapped around a mononucleosome plus linker) at concentrations of ~5–30 ng/mL in healthy individuals (higher in disease states). The clinical breakthrough came with the realization that cfDNA from specific tissues or pathological processes could be detected against the background of normal cfDNA: (1) non-invasive prenatal testing (NIPT) — fetal cfDNA (derived from placental trophoblast cells) constitutes ~10–20% of total maternal cfDNA by the first trimester; detection of extra copies of chromosomes 21, 18, or 13 in maternal blood enables screening for Down syndrome and other aneuploidies with >99% sensitivity and >99.5% specificity, largely replacing invasive amniocentesis for initial screening (Dennis Lo, 1997 — discovery of fetal cfDNA in maternal blood); (2) circulating tumor DNA (ctDNA) — tumor-derived cfDNA carrying cancer-specific mutations, methylation changes, and copy number alterations; enables "liquid biopsies" for cancer detection, treatment monitoring, residual disease detection, and resistance mutation identification; (3) organ transplant rejection monitoring — donor-derived cfDNA in recipient blood indicates graft injury.

1. VERIFIED CLAIMS (Tier 1 — Peer-Reviewed / Established)

1.1 Biology of cfDNA

• Mandel and Métais (1948): first reported the presence of cell-free nucleic acids in blood — largely ignored for decades
• Origin: cfDNA is released primarily through apoptosis (programmed cell death — produces characteristic ~167 bp mononucleosome-sized fragments) and necrosis (produces larger, more heterogeneous fragments); smaller contributions from active secretion and NETosis (neutrophil extracellular trap formation)
• Half-life: short (~16 minutes to 2 hours) — cleared rapidly by the liver, kidney, and nucleases; this short half-life makes cfDNA a real-time indicator of biological processes
• Normal concentration: ~5–30 ng/mL in healthy adults; elevated in pregnancy, exercise, trauma, infection, inflammation, and cancer

1.2 Non-Invasive Prenatal Testing (NIPT)

• Dennis Lo et al. (1997): demonstrated the presence of fetal (Y-chromosome) DNA in maternal plasma — establishing that the placenta releases cfDNA into the maternal circulation
• NIPT for chromosomal aneuploidies (2011 — clinical introduction): counts the relative representation of chromosome 21 (and 18, 13, X, Y) sequences in maternal cfDNA using next-generation sequencing; an excess of chromosome 21 sequences indicates trisomy 21 (Down syndrome); >99% sensitivity, >99.5% specificity — the most accurate non-invasive screening test; has dramatically reduced the need for amniocentesis
• Expanded NIPT: newer versions detect microdeletions (22q11.2 — DiGeorge syndrome), single-gene disorders (Rh blood typing, cystic fibrosis), and genome-wide copy number variants

1.3 Circulating Tumor DNA (ctDNA)

• Tumor cells release DNA into the bloodstream through cell death and active secretion — ctDNA carries tumor-specific genetic alterations (point mutations, copy number changes, structural rearrangements, methylation patterns) that distinguish it from normal cfDNA
• Clinical applications:
• Treatment selection: identify actionable mutations (EGFR mutations in lung cancer, KRAS/BRAF in colorectal cancer) to guide targeted therapy — approved companion diagnostic tests exist
• Treatment monitoring: serial ctDNA measurements track tumor burden in real time; rising ctDNA levels indicate disease progression
• Minimal residual disease (MRD): detection of ctDNA after curative-intent surgery predicts recurrence months to years before radiographic detection
• Resistance mechanisms: identify resistance mutations (e.g., EGFR T790M) without repeat tissue biopsy

2. CREDIBLE CLAIMS (Tier 2 — Academic / Debated but Supported)

2.1 Multi-Cancer Early Detection (MCED)

• Galleri test (GRAIL/Illumina): uses cfDNA methylation patterns to detect >50 cancer types from a single blood draw — trained on methylation signatures that distinguish cancer-derived cfDNA from normal cfDNA; detects a cancer signal of origin (tissue of origin prediction); FDA breakthrough device designation; large-scale clinical trials (PATHFINDER, NHS-Galleri) are ongoing
• Sensitivity: varies by cancer stage (higher sensitivity for later stages, lower for Stage I) and cancer type; overall specificity >99.5% (low false-positive rate)
• Potential to shift cancer from late-stage to early-stage detection — but clinical utility (whether early detection translates to reduced mortality) requires prospective randomized trials

2.2 Transplant Monitoring

• Donor-derived cfDNA (dd-cfDNA): the fraction of cfDNA in a transplant recipient's blood that originates from the donor organ; elevated dd-cfDNA (>1% of total cfDNA) indicates active graft injury/rejection; validated for kidney, heart, and lung transplant monitoring; potential to replace or supplement invasive biopsies

3. SPECULATIVE CLAIMS (Tier 3 — Possible but Unverified)

3.1 Universal cfDNA Health Screening

• The vision of a single blood test that screens for dozens of cancers, organ damage, infections, and inflammatory conditions simultaneously using cfDNA analysis is technically plausible but not yet clinically validated; questions remain about cost-effectiveness, overdiagnosis risks, and the psychological impact of false positives

4. DUBIOUS CLAIMS (Tier 4 — No Credible Source / Contradicted by Evidence)

4.1 cfDNA Tests Replace All Biopsies

• [OVERSIMPLIFIED] Claims that liquid biopsies will completely replace tissue biopsies — while liquid biopsies provide valuable complementary information, tissue biopsy remains necessary for histological diagnosis, tumor microenvironment characterization, and many clinical decisions; cfDNA-based tests have limitations in early-stage disease and in tumors with low cfDNA shedding rates

COUNTER-ARGUMENTS AND CRITICAL PERSPECTIVES

False Positives in Multi-Cancer Early Detection

cfDNA-based multi-cancer early detection (MCED) tests, such as the Galleri test (Liu et al. 2020), detect methylation signatures associated with cancer. However, the positive predictive value in asymptomatic populations with low cancer prevalence is modest — most positive results in screening populations are false positives, leading to invasive follow-up imaging and biopsies, psychological distress, and healthcare costs. Whether early detection via cfDNA screening ultimately reduces cancer mortality remains unproven in randomized trials as of 2025.

Tumor Shedding Heterogeneity Limits Sensitivity

cfDNA shedding varies enormously across cancer types, stages, and individual tumors. Brain tumors, renal cell carcinomas, and many early-stage cancers (Stage I) shed little or no detectable ctDNA into peripheral blood, making liquid biopsies unreliable for these cases. The promise of "one blood test for all cancers" oversimplifies the biological variability of tumor DNA release into circulation.

Clonal Hematopoiesis Confounds Cancer Detection

Age-related clonal hematopoiesis of indeterminate potential (CHIP) — somatic mutations in blood cell precursors unrelated to cancer — produces mutant cfDNA fragments that can be misinterpreted as tumor-derived. CHIP-associated mutations (DNMT3A, TET2, ASXL1) are common in adults over 60 and represent a major source of false-positive cancer signals in cfDNA assays, requiring sophisticated bioinformatic filtering to distinguish from true tumor mutations.

Cost-Effectiveness Not Established for Population Screening

Current cfDNA screening tests cost $900–$1,000 per assay, and no health economic analysis has yet demonstrated cost-effectiveness for population-level cancer screening. The combination of test costs, downstream diagnostic workup expenses, and uncertain mortality benefits makes the economic case for cfDNA-based screening unresolved. Insurance coverage and health system adoption depend on forthcoming randomized trial results.

IMAGES

No images assigned yet.

BIBLIOGRAPHY

1. Lo, Y | 1997 | "Presence of Fetal DNA in Maternal Plasma and Serum" | The Lancet | ∅ | 350.9076::485–487 | M | ∅ | doi:10.1016/s0140-6736(97)02174-0 | ∅ | ∅ | Dennis, et al.
2. Wan, Jonathan C | 2017 | "Liquid Biopsies Come of Age: Towards Implementation of Circulating Tumour DNA" | Nature Reviews Cancer | ∅ | 17.4::223–238 | M., et al | ∅ | doi:10.1038/nrc.2017.7 | ∅ | ∅ | ∅
3. Mandel, P.; P | 1948 | "Les Acides Nucléiques du Plasma Sanguin Chez l'Homme" | Comptes Rendus des Séances de la Société de Biologie et de Ses Filiales | ∅ | 142::241–243 | Métais | ∅ | doi:10.3406/crai.1881.68731 | ∅ | ∅ | ∅
4. Chiu, Rossa W | 2008 | "Noninvasive Prenatal Diagnosis of Fetal Chromosomal Aneuploidy by Massively Parallel Genomic Sequencing of DNA in Maternal Plasma" | Proceedings of the National Academy of Sciences | ∅ | 105.51::20458–20463 | K., et al | ∅ | doi:10.1073/pnas.0810641105 | ∅ | ∅ | ∅
5. Liu, Minetta C., et al | 2020 | "Sensitive and Specific Multi-Cancer Detection and Localization Using Methylation Signatures in Cell-Free DNA" | Annals of Oncology | ∅ | 31.6::745–759 | ∅ | ∅ | doi:10.1016/j.annonc.2020.04.013 | ∅ | ∅ | ∅
6. Tie, Jeanne, et al. ra92 | 2016 | "Circulating Tumor DNA Analysis Detects Minimal Residual Disease and Predicts Recurrence in Patients with Stage II Colon Cancer" | Science Translational Medicine | ∅ | 8.346::346 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
7. Snyder, Matthew W., et al | 2016 | "Cell-Free DNA Comprises an In Vivo Nucleosome Footprint That Informs Its Tissues-of-Origin" | Cell | ∅ | 164.1::57–68 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
8. Sigdel, Tara K., et al. e79 e85 | 2019 | "A Computational Method for the Measurement of Donor-Derived Cell-Free DNA" | Transplantation | ∅ | 103.6:: | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
9. Schwarzenbach, Heidi, Dave S | 2011 | "Cell-Free Nucleic Acids as Biomarkers in Cancer Patients" | Nature Reviews Cancer | ∅ | 11.6::426–437 | B | ∅ | ∅ | ∅ | ∅ | Hoon, and Klaus Pantel
10. Bettegowda, Chetan, et al. ra24 | 2014 | "Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies" | Science Translational Medicine | ∅ | 6.224::224 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
11. Heitzer, Ellen, et al | 2019 | "Current and Future Perspectives of Liquid Biopsies in Genomics-Driven Oncology" | Nature Reviews Genetics | ∅ | 20.2::71–88 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
12. Diaz, Luis A., Jr; Alberto Bardelli | 2014 | "Liquid Biopsies: Genotyping Circulating Tumor DNA" | Journal of Clinical Oncology | ∅ | 32.6::579–586 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
13. Mouliere, Florent, et al. eaat4921 | 2018 | "Enhanced Detection of Circulating Tumor DNA by Fragment Size Analysis" | Science Translational Medicine | ∅ | 10.466:: | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
14. Thierry, Alain R., et al | 2016 | "Origins, Structures, and Functions of Circulating DNA in Oncology" | Cancer and Metastasis Reviews | ∅ | 35.3::347–376 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
15. Jahr, Sabrina, et al | 2001 | "DNA Fragments in the Blood Plasma of Cancer Patients: Quantitations and Evidence for Their Origin from Apoptotic and Necrotic Cells" | Cancer Research | ∅ | 61.4::1659–1665 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
16. Newman, Aaron M., et al | 2014 | "An Ultrasensitive Method for Quantitating Circulating Tumor DNA with Broad Patient Coverage" | Nature Medicine | ∅ | 20.5::548–554 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
17. Alix-Panabières, Catherine; Klaus Pantel | 2016 | "Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy" | Cancer Discovery | ∅ | 6.5::479–491 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
18. De Vlaminck, Iwijn, et al. ra77 | 2014 | "Circulating Cell-Free DNA Enables Noninvasive Diagnosis of Heart Transplant Rejection" | Science Translational Medicine | ∅ | 6.241::241 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
19. Lo, Y | 2010 | "Maternal Plasma DNA Sequencing Reveals the Genome-Wide Genetic and Mutational Profile of the Fetus" | Science Translational Medicine | ∅ | 2.61::61 | M | ∅ | ∅ | ∅ | ∅ | Dennis, et al. ra91
20. Cristiano, Stephen, et al | 2019 | "Genome-Wide Cell-Free DNA Fragmentation in Patients with Cancer" | Nature | ∅ | 570::385–389 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
21. Moss, Joshua, et al | 2018 | "Comprehensive Human Cell-Type Methylation Atlas Reveals Origins of Circulating Cell-Free DNA in Health and Disease" | Nature Communications | ∅ | 9::5068 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅

CROSS-REFERENCE INDEX

Generated from V4 expansion plan. Last Updated: March 11, 2026

Corrections

• 1 truncated DOI in the bibliography reassembled — Elsevier identifiers of the form 10.1016/0004-6981(72)90076-5 contain a parenthesised year, and an upstream parse treated the opening bracket as a field break: each DOI was cut short and its tail ()90076-5) left stranded in a neighbouring column. The two halves were rejoined from this same line — it was then confirmed to resolve against Crossref before being written, so no identifier was reconstructed on faith. Repaired: 10.1016/s0140-6736(97)02174-0. Corpus hygiene campaign, Phase 4, 2026-07-29.